Skip to main content

This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.

Publisher: Bentham Science Publishers

Volume 6, Number 4, December 2006

Articles

Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets
pp. 305-311(7)
Authors: Fernandez, David; Bonilla, Eduardo; Phillips, Paul; Perl, Andras

Favourites:
ADD

Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis
pp. 313-321(9)
Authors: Vielhauer, Volker; Anders, Hans-Joachim

Favourites:
ADD

Type I Interferon as a Target of Treatment in SLE
pp. 323-330(8)
Authors: Lee, P. Y.; Reeves, W. H.

Favourites:
ADD

Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
pp. 331-343(13)
Authors: Munuswamy-Ramanujam, G.; Khan, K. A.; Lucas, A. R.

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

NF-κ B and Rheumatic Diseases
pp. 359-372(14)
Author: Okamoto, Takashi

Favourites:
ADD

Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
pp. 373-381(9)
Authors: Nakahara, Hideko; Nishimoto, Norihiro

Favourites:
ADD

Role of PGE2 and EP Receptors in the Pathogenesis of Rheumatoid Arthritis and as a Novel Therapeutic Strategy
pp. 383-394(12)
Authors: Akaogi, Jun; Nozaki, Toshiko; Satoh, Minoru; Yamada, Hidehiro

Favourites:
ADD

Targeting Fibrosis in Systemic Sclerosis
pp. 395-400(6)
Author: Lafyatis, Robert

Favourites:
ADD

Targeting Vascular Disease in Systemic Sclerosis
pp. 401-407(7)
Author: Kowal-Bielecka, Otylia

Favourites:
ADD
Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more